Israel’s Teva Device Unit Accused Of False Claim In IPO Prospectus
This article was originally published in PharmAsia News
Executive Summary
A Teva Pharmaceuticals unit, Optical Imaging, apparently said in an initial public offering prospectus one of its drugs had U.S. FDA approval, contrary to fact